Roles of CD5+, CD19+, CD41a+, CD55+ and CD59+ in Chronic Immune Thrombocytopenic Purpura (ITP).
Loading...
Date
2014-01-11
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Aims: The aim of this study was to investigate of the roles of CD5+ and CD19+ on
lymphocytes, CD5+ on B lymphocytes, CD41a+ on platelets and CD55+ and CD59+ on
erythrocytes in platelet destruction; and evaluate them according to the patient response
status to steroid therapy and platelet counts in chronic immune thrombocytopenic
purpura (ITP).
Study Design: This study included 20 chronic ITP patients and 20 healthy controls. We
investigated the roles of CD5+ and CD19+ expression on lymphocytes, CD5+ expression
on B lymphocytes, CD41a+ expression on platelets, and CD55+ and CD59+ expression
on erythrocytes, as well as the platelet counts in healthy and chronic ITP patients.
Additionally, these markers were evaluated according to the patient response status to
steroid therapy and platelet counts.
Place and Duration of Study: This study took place at the Department of Internal
Medicine and Haematology, Meram Medical Faculty at Selçuk University in Turkey, between November, 2008 and July, 2009.
Methodology: A total of 40 patients (26 women, 14 men, age range: 19-79 years) were
studied. The study group included 20 chronic ITP patients (12 women and 8 men, age
range: 19-78 years) and the control group included 20 healthy volunteers (14 women
and 6 men, age range: 22-79 years). The platelet counts and expressions of CD5+ and
CD19+ on lymphocytes, CD5+ on B lymphocytes, CD41a+ on platelets, and CD55+ and
CD59+ on erythrocytes were analysed in the patients and control subjects. The chronic
ITP patients were evaluated according to their requirements of treatment. Five patients
whose platelet counts were above 50,000 mm–3 were observed without treatment. The
other 15 patients whose platelet counts were under 50.000 mm–3 and had bleeding, or
whose platelet counts were under 20,000 mm–3, were given methylprednisolone
treatments (1 mg/kg/day orally). Three of the 15 patients discontinued treatment for
various reasons. The twelve patients who continued the methylprednisolone treatment
were divided into two subgroups according to their responder status of steroid treatment.
The patients whose platelet counts slowly increased above 30,000 mm–3 within three
months included the steroid treatment responder subgroups.
The chronic ITP patients were also divided into two subgroups according to the severity
of their thrombocytopenia. The limit of the platelet count was 30,000 mm–3 for severe
thrombocytopenia. These parameters were analysed according to the response status of
the steroid treatment and platelet counts. The platelet counts, and the expressions of
these markers, were compared between the subgroups.
Results: The level of CD5+ on B lymphocyte expression (2.19 ± 1.65) in peripheral blood
lymphocytes was significantly higher in the immune thrombocytopenic purpura patients
than in the controls (P = .05). The CD55+ + CD59+ expression on erythrocytes (98.03 ±
1.77) was significantly higher in the ITP patients than in the controls (P = .05). There was
no significant relationship between the expression of CD5+, CD19+ or CD5+ on B
lymphocytes, CD41a+ expression on platelets or CD55+ and CD59+ expression on
erythrocytes, according to the response status to steroid therapy in the patient group (P
> 0.05). Additionally, the patients were evaluated according to platelet counts, and there
was a significantly positive correlation between the level of CD41a+ expression on the
platelets and the platelet count (P = .05).
Conclusion: The level of CD5+ on B lymphocytes was significantly higher in the ITP
patients than in the controls. A relationship between CD55+ plus CD59+ expression on
erythrocytes and immune destruction of platelets was not observed in the chronic ITP
patients.
Description
Keywords
Chronic ITP, pathogenesis, CD5, CD19, CD55, CD59, CD41a
Citation
Kaya Fatma, Berber Llhami, Erkurt Mehmet Ali, Aydogdu Ismet, Reisli Lsmail. Roles of CD5+, CD19+, CD41a+, CD55+ and CD59+ in Chronic Immune Thrombocytopenic Purpura (ITP). British Journal of Medicine and Medical Research. 2014 Jan; 4(2): 660-670.